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Abstract
Introduction: The chromodomain helicase DNA binding protein 5 (CHD5) has recently been identified as a tumor
suppressor in a mouse model. The CHD5 locus at 1p36 is deleted, and its mutation has been detected in breast
cancer. We, therefore, evaluated whether CHD5 plays a role in human breast cancer.
Methods: We screened mutations in 55 tumors, determined promoter methylation in 39 tumors, measured RNA
expression in 90 tumors, analyzed protein expression in 289 tumors, and correlated expression changes with
clinicopathological characteristics of breast cancer. Functional effects of CHD5 on cell proliferation, invasion and
tumorigenesis were also tested.
Results: Although only one mutation was detected, CHD5 mRNA expression was significantly reduced,
accompanied by frequent genomic deletion and promoter methylation, in breast cancer. The extent of methylation
was significantly associated with reduced mRNA expression, and demethylating treatment restored CHD5
expression. Lower CHD5 mRNA levels correlated with lymph node metastasis (P = 0.026). CHD5 protein expression
was also reduced in breast cancer, and lack of CHD5 expression significantly correlated with higher tumor stage,
ER/PR-negativity, HER2 positivity, distant metastasis and worse patient survival (P ≤ 0.01). Functionally, ectopic
expression of CHD5 in breast cancer cells inhibited cell proliferation and invasion in vitro and tumorigenesis in
nude mice. Consistent with the inhibition of invasion, CHD5 down-regulated mesenchymal markers vimentin,
N-cadherin and ZEB1 in breast cancer cells.
Conclusion: Down-regulation of CHD5, mediated at least in part by promoter methylation, contributes to the
development and progression of human breast cancer.
Introduction
Tumorigenesis is a multi-step process that results from
progressive accumulation of genetic and epigenetic
alterations in different genes. Chromosomal loss, which
leads to the inactivation of tumor suppressor genes, is
one of the most common genetic alterations detected in
human cancer. Previous publications have documented
that the p36 band of chromosome 1, 1p36, is frequently
deleted in a wide range of human cancers, including
those of epithelial, neural and hematopoietic origin [1].
Recently, Bagchi et al. identified CHD5, which localizes
to the deletion region at 1p36, as a tumor suppressor
gene through functional analysis in a mouse model.
Chd5 knock-down was associated with hyperprolifera-
tion and reduced apoptosis and senescence, primarily
through the p19Arf/p53 pathway [2].
CHD5 belongs to the chromodomain helicase DNA
binding domain (CHD) family, which is a subclass of
the Swi/Snf proteins [3,4]. Of nine members of the
CHD family (CHD1-CHD9), two (CHD3 and CHD4)
are components of the nucleosome remodeling and
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histone deacetylation (NuRD) complex and play an
important role in chromatin remodeling [5,6]. As CHD5
shares the same functional domain with CHD3 and
CHD4, it may also modulate chromatin remodeling and
thus affect normal development and cancer.
Evidence that CHD5 functions as a tumor suppressor
in human cancer has principally come from studies of
neuroblastoma, in which CHD5 mRNA expression was
down-regulated likely through promoter methylation in
tumors, and high expression of CHD5 was statistically
associated with better patient survival [7]. Furthermore,
ectopic expression of CHD5 in neuroblastoma cell lines
suppressed clonogenicity and tumor growth [6,7].
Hypermethylation of CHD5 promoter has also been
detected in gastric, colorectal and ovarian cancers, and
somatic mutations have been detected in ovarian cancer
[8-11]. However, whereas 1p36 is commonly deleted in
human breast cancers, the role of CHD5 in breast can-
cer has not been evaluated.
We hypothesize that CHD5 is a tumor suppressor gene
in breast cancer and tested this hypothesis in this study.
We examined CHD5 for somatic mutation, copy number
changes, mRNA and protein expression, and promoter
methylation in primary tumors and cell lines from
human breast cancer. In addition, we assessed its effect
on cell proliferation in vitro and in vivo. We found that
while CHD5 mutation was relatively rare, it had frequent
down-regulation, hemizygous deletion and promoter
methylation. Promoter hypermethylation correlated with
lower levels of CHD5 mRNA expression, and demethylat-
ing treatment decreased promoter methylation and
increased CHD5 expression, suggesting that promoter
methylation is responsible at least in part for reduced
CHD5 expression in breast cancer. Interestingly, reduced
CHD5 expression significantly correlated with lymph
node metastasis, recurrence and shorter patient survival
in breast cancer. In addition, ectopic expression of CHD5
suppressed cell proliferation and tumor growth of the
MDA-MB-231 cell line by arresting cell cycle at the G0/
G1 phase, and inhibited invasiveness of MDA-MB-231
and Hs 578T cells in vitro. Our results strongly support a
tumor suppressor role for CHD5 in breast cancer.
Materials and methods
Cell lines and tissues
In total, 32 breast cancer cell lines (BT-20, BT-474, BT-
549, BT-483, CAMA-1, DU4475, HCC1143, HCC1395,
HCC1500, HCC1599, HCC1806, HCC1937, HCC202,
HCC2218, HCC38, HCC70, Hs 578T, MCF7, MDA-MB-
134, MDA-MB-157, MDA-MB-175, T-47D, MDA-MB-
231, MDA-MB-361, MDA-MB-415, MDA-MB-453,
MDA-MB-468, SW527, UACC893, ZR-75-1, ZR-75-30,
BRF-71T) and two immortalized non-neoplastic breast
epithelial cell lines (184A1 and BRF-97T) were used in
this study. Of these, BRF-97T and BRF-71T were pur-
chased from Biological Research Faculty & Facility
(BRFF, Ijamsville, MD, USA), and the rest were pur-
chased from American Type Culture Collection (Mana-
ssas, VA, USA). The primary culture of human
mammary epithelial cells (HMEC) was purchased from
Cambrex (East Rutherford, NJ, USA). Cells were cultured
according to the manufacturers’ protocols.
Tumor tissues and adjacent normal tissues were
obtained from 377 breast cancer patients who received
surgery in the Cancer Hospital of Tianjin Medical Uni-
versity, Tianjin, China. Freshly frozen tissues from 107
patients were used to extract RNA or DNA samples, of
which 58 were stored in RNAlater® solution and used
for RNA extraction and CHD5 mRNA expression analy-
sis, 30 had bisulfite-treated DNA from a previous study
and were used for promoter methylation analysis (19 of
them also used for RNA expression analysis), and 38
were used for mutation detection. Formalin-fixed paraf-
fin-embedded primary tumor specimens from 289
patients were prepared in a tissue microarray format
and used for CHD5 protein expression analysis by
immunohistochemical (IHC) staining, which included 19
tumor specimens that were also used for mRNA expres-
sion and promoter methylation analyses. Samples were
from the tissue bank at the Cancer Hospital of Tianjin
Medical University and were used entirely based on
availability. Use of human tissues and clinicopathological
information was approved by the Institutional Ethics
Committee. Genomic DNA was extracted using the
DNeasy Blood & Tissue kit (Qiagen, Shanghai, China ),
and total RNA was isolated using the RNeasy Mini kit
(Qiagen).
The numbers of samples for different analyses were
different because we used samples from our previous
studies and many of them ran out of DNA, RNA or
bisulfite-treated DNA. The majority of specimens used
for IHC staining did not have DNA or RNA samples
available. All samples with a result for any readout were
included in this manuscript.
Real-time and semi-quantification PT-PCR
Reverse transcription reaction was performed using 2 μg
total RNA with M-MLV reverse transcriptase (Promega,
Madison, WI, USA). Real-time PCR reaction was per-
formed in 25 μl reaction volume using SYBR Premix
Ex Taq kit (TaKaRa, Dalian, China) and carried out on
an iQ5 Multicolor Real-Time PCR Detection System
(Bio-Rad, Hercules, CA, USA). The CHD5 expression
levels were normalized according to GAPDH in each
sample. Primers used for CHD5 real time PCR were 5’-
CAAGTGTAAAGGGAAGCGGAAGAAG-3’ (forward)
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and 5’-CTTTTTATTCGGGGAGTAGTCAC-3’ (reverse),
and those for GAPDH were 5’-GGTGGTCTCCTCTGAC
TTCAACA-3’ (forward) and 5’-GTTGCTGTAGC-
CAAATTCGTTGT-3’ (reverse). CHD5 mRNA expression
reading in HMEC was defined as 1, and CHD5 expression
levels for other samples were normalized accordingly. Pri-
mer sequences for CHD5 semi-quantification PCR were
5’-TGAAGAAACTGCGGGATG-3’ (forward) and 5’-
TGCCGAACTTGAGGATGT-3’ (reverse).
Mutation and methylation analysis
The 40 coding exons and adjacent splicing junctions of
CHD5 were amplified by PCR using previously reported
primers and procedures [12]. PCR products were purified
and sequenced (Invitrogen, Beijing, China). When a
sequence alteration was detected, PCR and sequencing
were repeated to confirm it. For confirmed alterations in
tumor samples, PCR and sequencing were performed in
matched normal samples to determine whether an altera-
tion was somatic or germline.
Promoter methylation analysis was conducted following
a published method [13]. Two pairs of primers, 5’-
TTTAGGGGTTTGTATGGGTTTTAG-3’ (F1)/5’-CCC
TCTCCAAAAAAAATTAAAAAA-3’ (R1) [7] and 5’-T
TTTTTTGGAGAGGGGGTTAGG-3’ (F2)/5’-CTATAA-
CAACCCCATCCCAT-3’ (R2), were used. These primers
amplify the CG rich region of the CHD5 promoter from
-841 to -246. Purified PCR products were cloned into
pMD18-T vector (TaKaRa, Dalian, China). At least eight
clones for each sample were sequenced. Methylation levels
for each CpG site were indicated by the ratio of methyla-
tion positive clones to the total number of clones
sequenced, and were categorized into three groups in cell
lines: high (ratio > 0.5), low (0 < ratio < 0.5) and none
(ratio = 0) (marked as dark, gray and white dots, respec-
tively.). The average methylation level at a CpG site was
also presented.
Copy number detection
Copy number changes in the CHD5 gene were detected by
real-time PCR using the SYBR Premix Ex Taq kit
(TaKaRa). Primer sequences for CHD5 were 5’-CTGTTG
CTGCAGTTCCTTCTC-3’ and 5’-ATGAAGGACA-
GAACCTGCCTG-3’. The RNaseP gene, which rarely has
copy number changes in tumors [14], was used as an
internal control for a stable diploid copy number. Primer
sequences for RNaseP were 5’-CCTGGTACATGCCACT-
GATG-3’ and 5’-AGTGTAGAGGGCAAGCCAGA-3’.
Briefly, 10 ng genomic DNA from each sample was used
as the template for PCR with either CHD5 or RNaseP pri-
mers in a volume of 20 μl. The final concentration for
each primer was 0.25 μM. CHD5 copy number was deter-
mined by dividing the ΔCt value for CHD5 by that for
RNaseP. For cell lines, the average CHD5/RNaseP ratio
among a pool of normal human genomic DNA (HGD)
was defined as 1 and used as the value for a normal gen-
ome, and a deletion was defined by a ratio that was 0.5 or
less. For primary tumors, a deletion was defined when the
CHD5/RNaseP ratio in a tumor was about half or less of
that in its matched non-cancerous tissue.
Western blotting
Western blotting was performed according to a published
protocol [15]. Antibodies for the following proteins were
used: CHD5 (rabbit polyclonal, 1:1,000 dilution, Strategic
Diagnostics, Newark, DE, USA), b-actin (A1978, Sigma-
Aldrich, Beijing, China), p21 (#610233, BD Biosciences,
Franklin Lakes, NJ, USA), p53 (sc-47698, Santa Cruz Bio-
technology, Santa Cruz, CA, USA), vimentin (#3932, Cell
Signaling Technology, Beverly, MA, USA), N-cadherin
(#610920, BD Biosciences), E-cadherin (#3195, Cell Signal-
ing) and ZEB1 (sc-25388, Santa Cruz Biotechnology).
Immunohistochemical (IHC) staining
Immunohistochemical analysis was performed as pre-
viously described [16], using polyclonal rabbit anti-CHD5
antibody (1:2,000 dilution). The pre-immune serum was
used as the negative control. In evaluating the specificity
of the CHD5 antibody, we made cell pellets of ZR-75-1
(CHD5-negative) and T-47D (CHD5-positive) cells in
agarose, fixed them in formalin, embedded in paraffin, pre-
pared sections, and then conducted IHC staining. Detec-
tion of strong signals in T-47D but no signals in ZR-75-1
cells validated the antibody for IHC staining.
Protein expression levels of CHD5 were calculated by
multiplying the intensity of nucleus staining (0 = no stain-
ing, 1 = low intensity, 2 = medium intensity, and 3 = high
intensity) with the percentage of positively stained cells
(0 = no, 1 = 1 to 25%, 2 = 26 to 50%, 3 = 51 to 100%). A
combined index (intensity score × percentage score) of 0
or 1 was considered as negative staining (-), while an
index of 2 or 3 as weak staining (+), 4 to 6 as moderate
staining (++), and 9 as strong staining (+++). In statistical
analysis, CHD5 expression levels were categorized into
two groups: lack of expression (-) and weak to strong
expression (+, ++, and +++).
Colony formation assay
The CHD5 expression plasmid was constructed by clon-
ing the coding region of CHD5 into the pcDNA3.0
vector (Invitrogen). MDA-MB-231 cells were seeded in
6-well plates at a density of 5 × 105 cells per well and
transfected by using the lipofectamine 2000 reagent
(Invitrogen, Beijing, China). Forty-eight hours after
transfection, one well of cells was harvested to confirm
CHD5 expression, and the remaining wells were cul-
tured in selection medium containing 800 μg/ml G418
(Sigma) for two weeks. Cells were then fixed, stained
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with sulforhodamine B (SRB), and measured for optical
intensities, which indicated cell numbers, as described in
our previous publication [17].
RNA interfering
Small-interfering RNAs (siRNAs) for the CHD5 gene were
purchased from Qiagen and Invitrogen. Two of them,
named Q7 (Qiagen) and I20 (Invitrogen), were confirmed
to be capable of knocking down CHD5 and thus were
used. The target sequence of Q7 was 5’-ACGGTACAT-
GATCCTCAACGA-3’ and that of I20 was 5’-CAG-
CAGTTCTGCTTCCTCCTCTCAA-3’. A siRNA that
does not target any known genes was purchased from Rui
Bo (Guangzhou, China) and used as a control. The Lipo-
fectamine RNAiMAX transfection reagent (Invitrogen)
was used to transfect siRNAs into cells following the man-
ufacturer’s instruction.
Flow cytometric cell cycle analysis
MDA-MB-231 cells transfected with pcDNA3.0 vector or
CHD5 expression plasmid were selected using G418 (800
μg/ml; Sigma) for two weeks. 1 × 106 cells of each group
were collected, fixed with 70% ethanol for 24 hours,
washed and re-suspended with phosphate-buffered saline
(PBS), incubated with propidium iodide (20 mg/ml,
Sigma) and Rnase A (20 mg/ml) for 30 min in the dark,
and analyzed on a BD FACSCalibur flow cytometer
(Franklin Lakes, NJ, USA).
Cell proliferation analysis
After transfection and selection with G418 for two weeks,
MDA-MB-231 cells were harvested, diluted into five cells/
ml using selection medium, plated into 96-well plates at
100 μl per well, and cultured for another two to three
weeks. Cells surviving in a well were propagated and con-
firmed for CHD5 expression. Parental or clones of trans-
fected cells were plated into 12-well plates at 3 × 104 cells/
well, cultured for different times, fixed, stained with SRB
and measured for cell numbers.
Hs 578T cells were also transfected with CHD5-expres-
sing plasmid or control plasmids using lipofectamine 2000
reagent. After selection using G418 (400 μg/ml) for two
weeks, the population cells of each group were plated into
12-well plates and used for cell proliferation analysis.
Tumor growth assay
One × 106 parental or clones of transfected MDA-MB-
231cells were mixed with Matrigel (BD Biosciences, San
Jose, CA, USA) and injected subcutaneously into four
weeks old female BALB/c nude mice (eight mice for each
group). Tumor volumes were measured once a week and
calculated as below: L × W2 × 0.523 mm3, where L and
W indicate the length and the width of a tumor. Mice
were sacrificed at five weeks after injection, and tumors
were surgically removed, weighed, and fixed in 4% forma-
lin. Hematoxylin and eosin staining was performed for
histological examination. The animal experiment was
approved by the animal care and use center of Nankai
University, Tianjin, China.
Invasion assay
The Boyden chamber assay was used for invasion assay.
Briefly, 1 × 105 cells suspended in 200 μl serum-free
medium were plated into the top chamber with 50 μl
Matrigel-coated membrane (8 μM pole size, BD Bios-
ciences, Shanghai, China). The chambers were then
placed into 24-well plates with 600 μl serum-containing
(10%) medium in each well. After 24 hours incubation,
cells on the bottom side of the chamber membrane were
fixed, stained with crystal violet, and photographed.
Statistics
The SPSS 15.0 software package (SPSS Inc, Chicago, IL,
USA) was used for statistical analysis. Correlations
between CHD5 expression and clinicopathological vari-
ables were evaluated by Chi-square (c2) test. Progression-
free survival (PFS) and overall survival (OS) rates were
estimated by the Kaplan-Meier analysis. The Cox propor-
tional hazard regression analysis was performed for the
identification of relevant prognostic factors. For tumori-
genesis experiments, tumor sizes or weights between two
groups were analyzed using the Student’s t test. The statis-
tical analysis was two-sided and P-values less than 0.05
were considered as statistically significant.
Results
Mutation and copy number changes of CHD5 in breast
cancer
Sequencing the coding exons and adjacent splicing junc-
tions of CHD5 in 38 primary tumors and 17 cell lines of
breast cancer identified only one heterozygous frameshift
mutation (3215delG) in the MDA-MB-231 cell line. A
novel single nucleotide polymorphism (SNP) (470C > T,
Thr157Met) at the N-terminal region of CHD5 was
detected in two tissue samples. In addition, eight known
SNPs (previously reported in the SNP database) were
detected in the primary tumors and/or cell lines. All
sequence alterations, including known SNPs identified in
this study, are summarized in Table 1.
Changes in CHD5’s copy number were determined in
29 breast cancer cell lines and 15 paired breast cancer tis-
sues by real-time PCR with a pool of normal human
genomic DNA as the control for normal genome.
Whereas no homozygous deletion was detected, 5 of the
29 (17%) cell lines and 3 of the 15 (20%) primary tumors
showed a deletion in one to the two CHD5 copies. In
addition, 5 of the 29 (17%) cancer cell lines had an
increased copy number (Figure 1).
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Down-regulation of CHD5 in breast cancer
CHD5 mRNA expression was determined in 32 cell lines
and 58 primary tumors of breast cancer by real time PCR.
Compared to HMEC, 20 of 32 cancer cell lines (62.5%)
showed reduced expression of CHD5 by at least 50%, and
17 (53.1%) had an reduction by at least 75%. While six cell
lines (18.8%) did not have obvious expression changes, the
remaining six cell lines (18.8%) showed an increased
expression of CHD5 by at least one fold (Figure 2A).
CHD5 protein expression was confirmed in six breast can-
cer cell lines and HMEC cells by Western blotting. Consis-
tent with real time PCR results in cell lines, CHD5 protein
was strongly expressed in T-47D and HMEC, moderately
expressed in BT549 and MCF-7, but not detectable in
MDA-MB-361, MDA-MB-231 and Hs 578T (Figure 2B).
All six, except the BT549 cell line, had a normal CHD5
copy number.
Compared to matched adjacent noncancerous tissues,
37 of 58 primary tumors (63.8%) showed a reduced
CHD5 mRNA expression by at least 50%, 17 (29.3%) had
little change, and 4 (6.9%) had an increased CHD5
expression. In 20 of the 58 (34.5%) tumors, CHD5 was
down-regulated by at least 75%. Representative results
from 11 paired samples are shown in Figure 2C. Statisti-
cal analysis demonstrated that CHD5 mRNA expression
was significantly reduced in breast tumors compared to
their matched normal tissues (independent t-test, P <
0.05, Figure 2D). Furthermore, reduced CHD5 mRNA
expression significantly correlated with lymph node
metastasis (Mann-Whitney U test, P < 0.05), but not with
age at diagnosis or the status of p53, ER, PR and HER2
(Additional file 1 Table S1).
CHD5 protein expression was examined in 289 forma-
lin-fixed paraffin-embedded tumors and 20 normal breast
tissues by IHC. We first examined the specificity of the
CHD5 antibody in IHC staining (Figure 3A). CHD5 pro-
tein was positively identified in the nucleus of all 20 nor-
mal tissues (Figure 3B, Additional file 1 Table S2). In the
breast cancer tissues, while 145 (50.2%) tumors showed
various levels of CHD5 protein expression, 144 of them
(49.8%) showed no obvious CHD5 expression (Figure 3D-
G, Additional file 1 Table S2). Statistical analysis indicated
that lack of CHD5 expression significantly corrected with
higher histological grade (P = 0.01), more HER2 positive
tumors (P < 0.001), and less ER- (P = 0.009) or PR-positive
(P = 0.001) tumors (Table 2). According to molecular
classification of breast cancer, more CHD5-positive breast
cancers belonged to the luminal A subtype (ER+ and/or
PR+, HER2-), while more CHD5-negative tumors
belonged to the luminal B (ER+ and/or PR+, HER2+),
HER2 (ER-, PR-, HER2+), or the triple negative subtype
(ER-, PR-, HER2-) (P < 0.001). No association was
detected between CHD5 expression and patient age at
diagnosis, tumor size, lymph node metastasis, or family
history (Table 2).
Among the 289 patients, 242 received adjuvant che-
motherapy, 132 received endocrine treatment, and 91
received radiation therapy. The average follow-up time
was 61 months (ranged from 11 to 72 months). During
the follow-up, 3 patients (1%) developed local recurrence,
37 (12.8%) developed distant metastasis, and 24 (8.3%)
died. Lack of CHD5 expression significantly correlated
with distant metastasis (P < 0.001, Chi squared analysis)
and death (P = 0.001) (Table 2). Kaplan-Meier analysis
indicated that patients with no CHD5 expression had sig-
nificantly shorter progression-free survival (Figure 4A) and
overall survival (Figure 4B). Moreover, multivariate Cox
regression analysis indicates that lack of CHD5 expression
is an independent prognostic factor (Additional file 1
Table S3).
Promoter hypermethylation of CHD5 in breast cancer
The methylation status of the CHD5 promoter region from
-841 to -246, which contains 58 CpG sites and is frequently
methylated in neuroblastoma cell lines [7], was determined
in 9 breast cancer cell lines, 30 primary tumors, and 10
normal breast tissues. The majority of the 58 CpG sites
were methylated in breast cancer cell lines BT-20, MDA-
MB-231, ZR-75-30 and MDA-MB-175, while around half
of the 58 CpG sites were methylated in the MDA-MB-157
and BT-483 cancer cell lines (Figure 5A). In the remaining
three cancer cell lines (BRF-71T, HCC38 and BT-549),
CHD5 promoter methylation was detectable but to a much
lower extent (Figure 5A). Strikingly, the four cell lines with
the most extensive methylation (BT-20, MDA-MB-231,
Table 1 Mutation and single nucleotide polymorphisms








21 DelG3315 - 1/34 0/76
SNPs
4* C570T Thr157Met 0/34 3/76
4 G529C Leu 8/34 0/76
7 C1003T Phe 15/34 55/76
8 A1204G Val 16/34 55/76
12 C1957T Tyr 3/34 2/76
15 C2479T Asn 0/34 23/76
16 T2593C Ile 11/34 46/76
22 G3436A Ala 0/34 27/76
31 T4715C Ser1539Pro 26/34 0/76
Notes: 17 cell lines and 38 primary tumors of breast cancer were used. *
indicates the novel SNP identified in this study. The rest of the SNPs have
been reported in the SNP database (dbSNPs).
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ZR-75-30 and MDA-MB-175) had barely detectable CHD5
mRNA expression, and only one of the four cell lines, ZR-
75-30, had a copy number loss at CHD5 (Additional file 1
Table S4), suggesting that promoter methylation is more
often responsible for the down-regulation of CHD5 in
some breast cancers.
To further determine whether promoter methylation is
responsible for reduced CHD5 mRNA expression in
breast cancer, we treated MDA-MB-231 and Hs 578T
cell lines, both of which had little CHD5 mRNA expres-
sion, with the 5-aza-2’-deoxycytidine (5-aza-CdR)
demethylating agent (2 and 5 μM) for three days, and
examined the effect of 5-aza-CdR on CHD5 expression.
Real-time PCR assay showed that CHD5 mRNA level was
doubled in MDA-MB-231 cells and tripled in Hs 578T
cells after treatment with 2 μM 5-aza-CdR for three days,
and was quadrupled in both cell lines after treatment
with 5 μM 5-aza-CdR for three days (Figure 5B), which
are consistent with a previous study [9]. Treatment with
5 μM 5-aza-CdR could even increase CHD5 expression
at 12 and 24 hours in MDA-MB-231 cells (doubled at 12
hours and quadrupled at 24 hours) (Figure 5C). As
expected, sequencing of cloned bisulfite-treated DNA
demonstrated a significantly decreased methylation level
of CHD5 promoter in MDA-MB-231 cells treated with 5-
aza-CdR for 24 hours (Figure 5D).
In clinical specimens, the methylation level for each
CpG site was averaged in 10 normal breast tissues and 30
primary tumors and plotted against the location of each
CpG site (Figure 5E). The average methylation level per
CpG site was 0.1 in the tumor samples, which was signifi-
cantly higher than that in the normal samples (0.036)
Figure 1 Detection of CHD5 copy number changes in breast cancer. A total of 29 cell lines (A) and 15 primary tumors with matched
normal tissues (B) from breast cancer were used. A pool of normal human genome DNA was used as the normal control. Real-time PCR was
used for the detection, with the RNaseP gene as an internal control that rarely has copy number changes in cancers. T, tumor tissue; N, normal
breast tissue.
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Figure 2 Down-regulation of CHD5 mRNA expression in breast cancer. (A) Expression of CHD5 mRNA in breast cancer cell lines and primary
culture of human mammary epithelial cells (HMEC), as detected by real-time RT-PCR. GAPDH was used for normalization. The ratio CHD5/GAPDH
in HMEC was defined as 1, and the ratio in other cell lines was adjusted accordingly. (B) Detection of CHD5 protein expression in six breast
cancer cell lines and in HMEC cells by Western blotting. Actin was used as a loading control. (C) Representative results of CHD5 mRNA
expression in breast cancer samples and matched normal tissues, as detected by real-time RT-PCR using HMEC as a positive control. The ratio of
CHD5/GAPDH in HMEC was defined as 1, and that in other samples were normalized accordingly. (D) The distribution of CHD5 mRNA expression
values in the tumor group (n = 58) versus that in the normal group (n = 58) are shown in the plot-box diagram. The box ranges from the 25th
to the 75th percentile, and the bold line across the box indicates the median. The whiskers are 1.5 times of the quartile values.
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(independent t- test, P < 0.001). The CpG sites between
-626 and -399 were methylated more heavily in clinical
tumors (Figure 5E).
Among the 30 primary tumors used in the methyla-
tion study, 19 had adjacent normal tissue and, therefore,
were used for the detection of CHD5 expression by real
Figure 3 Immunohistochemical detection of CHD5 protein in normal tissues and primary tumors of the human breast. (A) Validation of
CHD5 antibody by detecting CHD5 protein in CHD5-positive T-47D cells but not in CHD5-negative ZR-75-1 cells by IHC with the CHD5
antibody. Rabbit preimmune IgG was used as the negative control. (B, C) Normal breast tissue stained with rabbit anti-CHD5 antibody (B) or
preimmune rabbit IgG (C, negative control). Arrows indicate cells that are positive for CHD5 staining. (D-G) Representative breast cancers
showing no CHD5 protein expression (D) and low (E), medium (F) and high (G) levels of CHD5 expression.
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time PCR. According to their average methylation levels,
we divided the 19 tumors into two groups: one with
lower levels of methylation (0 < average methylation
level < 0.036, 3 cases) and the other with higher levels
of methylation (average methylation level > 0.036, 16
cases). The same tumors were then divided into three
groups according to the levels of CHD5 expression: low
when CHD5 expression in a tumor was less than half of
that in the matched normal tissue, moderate when the
expression was more than half but less than two folds,
and high when the expression was more than two folds.
Notably, 12 of the 16 highly methylated tumors had low
levels of CHD5 expression, while the 3 tumors with
lower levels of methylation showed moderate or high
CHD5 expression (P = 0.045, Additional file 1 Table
S5). These results suggest that hypermethylation of
CHD5 promoter region is responsible for reduced
CHD5 mRNA expression at least in some of the breast
cancers.
CHD5 suppresses the proliferation of breast cancer cells
in vitro and in vivo
We transfected MDA-MB-231 breast cancer cells, which
have a truncation mutation of CHD5, with CHD5 expres-
sion plasmid or vector control. Expression of CHD5 was
confirmed by Western blotting (Figure 6A). After selection
with G418 for 12 and 16 days, expression of CHD5 signifi-
cantly decreased colony-forming efficiency (independent t-
test, P < 0.001) (Figure 6B, C). We also examined cell
cycle distribution of MDA-MB-231 cells after transfection
and selection with G418. CHD5 expression increased the
number of cells in G0/G1 phase while decreasing the
number of cells in the S and G2/M phases (Figure 6D, E).
Cell proliferation analysis was also conducted in Hs
578T cells, in which CHD5-expressing plasmid or control
plasmids were transfected, and the selection for positively
transfected cells continued for two weeks. Compared to
parental Hs 578T cells and those transfected with vector
control or the plasmid expressing antisense-CHD5, prolif-
eration activity of cells transfected with CHD5-expressing
plasmid was significantly reduced (Figure 6F).
In the T-47D breast cancer cell line, which expresses a
high level of CHD5, we knocked down CHD5 expression
by RNAi, and unexpectedly detected a significant decrease
in cell proliferation (Figure 6G).
The effect of CHD5 on cell proliferation was further
tested in parental and derivative stable clones of
MDA-MB-231 cells expressing varying levels of CHD5
(Figure 7A). Compared to parental MDA-MB-231 cells
and two vector control clones (V1 and V2), clones or
the population stably expressing CHD5 (S10, S14 and
Smix) showed significantly slower cell proliferation (Fig-
ure 7B). We also examined parental MDA-MB-231 cells,
the V1 vector control clone and the CHD5-expressing
stable population (Smix) or clone (S14) for tumorigen-
esis in nude mice. While the control cell populations
rapidly grew into tumors in nude mice, the CHD5-
expressing cells had significantly slower growth, as
Table 2 Correlation between CHD5 expression and
clinicopathological parameters in breast cancer
Parameters CHD5 expression (n) Total cases P-values
- +
Age (years) 289 0.590
≤ 50 67 62 129
> 50 78 82 160
Tumor size 288* 0.476
≤ 2 cm 29 34 63
> 2 cm 115 110 225
Histological grade 275* 0.010
I 4 14 18
II 100 103 203
III 34 20 54
pTNM stage 284* 0.105
I/II 99 111 210
III/IV 43 31 74
LN metastasis 289 0.215
- 57 67 124
+ 88 77 165
Estrogen receptor 289 0.009
- 66 44 110
+ 79 100 179
Progesterone receptor 289 0.001
- 84 54 138
+ 61 90 151
HER2 status 289 < 0.001
- 74 111 185
+ 71 33 104
Molecular subtype 289 < 0.001
luminal A 54 95 149
luminal B 35 12 47
HER2 37 20 57
Triple negative 19 17 36
Family history 264* 0.420
No 105 98 203
Yes 28 33 61
Distant metastasis 289 < 0.001
No 115 137 252
Yes 30 7 37
Death 289 0.001
No 125 140 265
Yes 20 4 24
Notes: LN, lymph node; pTNM, pathological tumor node metastasis; *, analysis
was limited to patients whose relevant information was available. Molecular
subtypes were defined as below: luminal A, ER+ and/or PR+/HER2-; luminal B,
ER+ and/or PR+/HER2+; HER2+, ER-/PR-/HER2+; and triple negative, ER-/PR-/
HER2-. CHD5 expression is categorized into two groups: lack of expression “-”
and expression at various levels “+”. P-values were determined by the Chi-
square (c2) test.
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indicated by tumor volumes measured at Weeks 3 to
5 and tumor weights determined at Week 5 (Figure 7C,
D). These results indicate that CHD5 suppresses breast
cancer cell growth both in vitro and in vivo.
CHD5 suppresses invasiveness of breast cancer cells in
vitro
The invasive ability of CHD5-expressing S10 and S14
clones were significantly impaired compared to parental
MDA-MB-231 cells and vector control cells (Figure 8A). In
the Hs 578T cell line, cell population stably transfected
with CHD5 also showed an inhibition of invasion when
compared to vector-transfected cell population (Figure 8B).
Consistent with a decrease in invasiveness, protein expres-
sion of vimentin, a mesenchymal cell marker, was reduced
in S10 and S14 cells (Figure 8C). In addition, protein
expression of N-cadherin and ZEB1, two mesenchymal cell
markers not detectable in MDA-MB-231 cells, were down-
regulated in CHD5-expression Hs 578T cells (Figure 8D).
Furthermore, knockdown of CHD5 in T-47D cells reduced
the expression of the epithelial marker E-cadherin and
increased the expression of mesenchymal marker vimentin
(Figure 8E), suggesting that CHD5 loss could induce EMT
in CHD5-positive breast cancer cells. EMT makers N-cad-
herin, ZEB1 and ZEB2 were also examined in T-47D cells,
but they were not detectable in this cell line. T-47D cells
were not invasive in the invasion assay, and knockdown of
CHD5 did not sufficiently induce invasiveness. These
results suggest that in addition to modulating cell cycle,
CHD5 also regulates cellular invasion by suppressing EMT
in breast cancer cells.
Discussion
Deletion of 1p36 is common in a variety of cancers,
including breast cancer, suggesting that there is an
important tumor suppressor gene in this region whose
inactivation drives tumorigenesis. By analyzing mouse
models generated by chromosome engineering to obtain
different dosages of genomic interval D4Mit190-51,
which corresponds to human 1p36, Bagchi et al. demon-
strated that CHD5 was the leading tumor suppressor
gene in this interval [2]. CHD5 has also been identified
as a candidate tumor suppressor gene in neuroblastoma
[18]. In this study, we conducted a series of studies to
examine whether CHD5 is a tumor suppressor gene in
human breast cancer. Whereas one mutation, a trunca-
tion mutation in the MDA-MB-231 breast cancer cell
line, was found in CHD5 among the samples examined,
CHD5 had frequent genomic deletion and promoter
methylation in both breast cancer cell lines and primary
tumors. Furthermore, promoter methylation correlated
with transcriptional down-regulation of CHD5 and
demethylating treatment increased CHD5 expression.
CHD5 protein expression was also significantly reduced
in primary breast tumors, and lack of CHD5 expression
correlated with higher tumor grade, local recurrence,
distant metastasis and worse patient survival. Function-
ally, CHD5 inhibited the proliferation and invasion of
MDA-MB-231 and Hs 578T cells in vitro and tumori-
genesis of MDA-MB-231 cells in vivo (Figures 1, 2, 3, 4,
5, 6, 7, 8). Taken together with previous findings that
showed deletion of 1p36 in breast tumors [19,20], our
results suggest that CHD5 is a tumor suppressor gene
Figure 4 Lack of CHD5 protein expression is significantly associated with worse patient survival. Kaplan-Meier analysis of progression-free
survival (A) and overall survival (B) in breast cancers with and without CHD5 protein expression. P-values were based on the log-rank test.
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Figure 5 Methylation of CHD5 promoter region down-regulates CHD5 expression in breast cancer. (A) Methylation status of CHD5 promoter
region in nine breast cancer cell lines as determined by bisulfite sequencing of cloned PCR products. The horizontal line at the top represents
promoter DNA, whereas vertical lines under it indicate the relative locations of each CpG site. Methylation status of each CpG site is indicated by
circles, and dark, gray and empty circles indicate high levels (methylation frequency > 50%), moderate levels (methylation frequency < 50%), and no
(methylation frequency = 0) methylation, respectively. (B, C) Detection of CHD5 mRNA levels by real time PCR in Hs 578T and MDA-MB-231 cell lines
treated with 2 and 5 μM 5-aza-2’-deoxycytidine (AZA) for 3 days (B) or in MDA-MB-231 cells treated with 5 μM AZA for 12 and 24 hours (h) (C). GAPDH
serves as an internal control. (D) Methylation levels of CHD5 promoter in MDA-MB-231 cells treated with AZA, as detected by bisulfite treatment and
sequencing of five clones from each PCR product. Empty, gray and dark circles indicate zero, one to three and four or five clones, respectively, that are
methylated. (E) Methylation levels of CHD5 promoter in breast tumors (n = 30) and normal breast tissues (n = 10). The frequency of methylation (y axis)
at each CpG site (x axis) was the average frequency in either the tumor or the normal group.
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whose inactivation by mutation, chromosomal deletion
or promoter methylation-mediated transcriptional
down-regulation plays a role in the development and
progression of breast cancer.
We noticed that in the T-47D breast cancer cell line,
which expresses a higher level of CHD5, RNAi-mediated
knockdown of CHD5 did not increase cell proliferation.
Unexpectedly, CHD5 knockdown decreased cell
proliferation. While the reason for this unexpected find-
ing remains to be determined, one possibility is that T-
47D cells have acquired molecular alterations that have
reversed the function of CHD5 from a proliferation sup-
pressor to a proliferation enhancer. Such a functional
reverse has been shown previously for some molecules.
For example, TGF-b is a potent tumor suppressor in
early stage tumorigenesis but becomes a promoter in
Figure 6 Effect of CHD5 on cell proliferation in breast cancer cell lines. (A) Confirmation of CHD5 expression in transfected MDA-MB-231
cells by Western blotting, with b-actin (ACTB) as a loading control. (B) Representative images of cells transfected with CHD5 or vector plasmid in
six-well culture plates at 12 days of G418 selection. (C) Ectopic expression of CHD5 in MDA-MB-231 cells decreased colony formation efficiency at
both 12 and 16 days of G418 selection, as detected by SRB staining. The numbers of cells are indicated by optical densities. (D, E) Ectopic
expression of CHD5 increased the number of cells in the G0/G1 phase but decreased the number of cells in the S phase of the cell cycle, as
determined by flow cytometer. Transfected cells were selected by G418, and pools A and B were a mixture of transfected MDA-MB-231 cells
from two independent transfection and selection experiments. (F) Ectopic expression of CHD5 inhibits cell proliferation in Hs 578T cells, as
measured by SRB staining assay. Parental cells without plasmid transfection (mock) and cells transfected with empty vector (vector control) and
antisense CHD5 were used as negative controls. (G) Knockdown of CHD5 expression by siRNAs (Q7 and I20) inhibits the proliferation of T-47D
cells as compared to parental cells (Mock) or siRNA control (Ctrl).
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late stage tumor progression [21]; and deacetylation
converts KLF5 from an anti-proliferative factor to a pro-
proliferative in epithelial cells [22].
A tumor-specific function-altering mutation is a well-
established indicator for tumor suppressor genes. In the
original study that identified 122 genes with somatic
mutations in breast cancer through large-scale DNA
sequencing, two of the 11 (18%) primary breast cancers
had a heterozygous missense mutation in CHD5 (133G >
A, V45M; 1999A > G, R667G) [12]. In our study, none of
the 38 primary tumors had somatic mutations in CHD5,
while one of the 17 breast cancer cell lines examined had
a frame shift mutation. Our results are consistent with
another report in which no mutations were detected in
60 breast cancer samples while three mutations were
identified in 123 ovarian cancer samples [11], indicating
that, although mutation of CHD5 could occur in breast
cancer, its frequency is rather low in primary tumors.
Among the SNPs detected in this study, some occurred
frequently in cell lines but were not detected in primary
tumors, including G529C (8/34 alleles or 24%) and
T4715C (76%); others occurred frequently in the primary
tumors but were not detected in any of the cell lines,
including C2479T (30%) and G3436A (36%). These dif-
ferences could be caused by differences in the ethnic
background of patients whose primary tumors were used
(Chinese) and patients from whom the cell lines were
derived (non-Chinese). There is also a possibility that
some of these SNPs contribute to successful establish-
ment of breast cancer cell lines or even breast cancer
progression, which remains to be determined.
Although somatic mutation of CHD5 is rare, obvious
down-regulation of CHD5 mRNA and protein was fre-
quent in breast cancer cell lines and primary tumors.
Hemizygous deletion and promoter methylation were
also common and could be responsible for transcriptional
down-regulation of CHD5 in breast cancer. In evaluating
the role of promoter methylation in the down-regulation
of CHD5, we found that transcriptional down-regulation
was significantly associated with promoter methylation
and that demethylating treatment significantly increased
CHD5 expression, indicting a role of methylation in
decreasing CHD5 mRNA expression. These results are
consistent with those from other types of tumors, such as
Figure 7 CHD5 inhibits the growth of breast cancer cells both in vitro and in nude mice. (A) Confirmation of CHD5 mRNA expression by
semi-quantification RT-PCR in parental MDA-MB-231 cells, stable vector control clones (V1 and V2), and stable population (Smix) and clones (S10
and S14) of CHD5-transfected cells. GAPDH was used as an internal control. (B) Expression of CHD5 inhibits cell proliferation in MDA-MB-231 cells,
as examined by SRB staining. (C, D) Expression of CHD5 represses tumor growth in nude mice, as indicated by tumor volumes (C) and tumor
weights (D) (8 mice were used for each group).
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neuroblastoma and ovarian cancer, in which frequent
promoter methylation and reduced RNA expression of
CHD5 had also been detected [7-10]. Therefore, methyla-
tion-mediated silencing, which is a common mechanism
for the inactivation of tumor suppressor genes, occurs at
CHD5 in different types of human cancers including
breast cancer.
Reduced CHD5 mRNA expression was significantly
associated with lymph node metastasis, while reduced
CHD5 protein expression significantly correlated to
recurrence, distant metastasis, progression-free survival
and overall survival in breast cancer. Multivariate Cox
regression analysis indicates that lack of CHD5 expres-
sion is an independent prognostic factor. These results
are consistent with a previous report where allelic loss at
1p was correlated with lymph node metastasis in breast
cancer [23] and that higher CHD5 expression was
strongly associated with more favorable outcomes in neu-
roblastoma. Furthermore, the only breast cancer cell line
harboring a truncated mutation at CHD5, MDA-MB-231,
is highly metastatic. Therefore, it is possible that inactiva-
tion of CHD5 contributes to metastatic progression of
breast cancer. Supporting this hypothesis, expression of
CHD5 in the metastatic MDA-MB-231 and Hs 578T
cells inhibited cellular invasiveness and down-regulated
EMT markers.
Activation of the p19Arf/p16Ink4a locus by CHD5, which
activates both p19Arf/p53 and p16Ink4a/Rb signal axes, has
been established as a mechanism for how CHD5 executes
its tumor suppressor function. However, the three breast
cancer cell lines used in our functional studies, MDA-
MB-231, Hs 578T and T-47D, harbor p53 mutations
[24], and no significant change in p53 expression was
detected in MDA-MB-231 cells expressing ectopic CHD5
or T-47D cells where CHD5 was knocked down (Figure
8C, E). Rb expression was not changed in CHD5-expres-
sing MDA-MB-231 cells either (data not shown). In addi-
tion, whereas the expression of p21, a target gene of p53
involved in cell cycle arrest, was increased in CHD5-
expressing MDA-MB-231 cells (Figure 8C), its expression
upon CHD5 knockdown in T-47D cells showed inconsis-
tent changes, as p21 expression was decreased by one
siRNA but not affected by another siRNA, although both
siRNAs efficiently knocked down CHD5 (Figure 8E). We
thus speculate that CHD5 suppresses breast carcinogen-
esis by a p53- and Rb-independent mechanism. In fact,
other mechanisms have been suggested in other types of
tumors, as CHD5 mutation or methylation is associated
Figure 8 CHD5 suppresses the invasion and the expression of EMT markers in breast cancer cells. (A, B) Expression of CHD5 inhibits the
invasion of MDA-MB-231 cells (A) and Hs 578T cells (B), as detected in the invasion assay. CHD5 or control is indicated at the top, and sample
names are indicated at upper left. (C-E) Detection of different proteins by Western blotting, including vimentin, p21 and p53 in MDA-MB-231
cells without transfection (Mock) or transfected with CHD5 plasmid (Smix population and S10 and S14 clones) or control plasmid (V1 and V2
clones) (C); N-cadherin, ZEB1 and vimentin in Hs 578T cell population expressing CHD5 (Smix) or vector (Vmix) (D); and E-cadherin, vimentin, p53
and p21 in T-47D cells without transfection (Mock) or transfected with negative control siRNA (Cont) and CHD5 siRNAs (Q7 and I20) (E).
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with KRAS or BRAF mutation in ovarian cancer [11], and
CHD5 expression correlates with MYCN amplification in
neuroblastoma [7,25].
Conclusions
In this manuscript, we found that promoter methylation,
genomic deletion and down-regulation of CHD5 at both
RNA and protein levels are common in breast cancer,
and CHD5 down-regulation was significantly associated
with metastasis and worse patient survival in breast can-
cer. In addition, in the highly metastatic MDA-MB-231
breast cancer cell line, which harbors a truncating muta-
tion, ectopic expression of CHD5 suppressed cell prolif-
eration in vitro and tumorigenesis in nude mice by
arresting the cell cycle, and inhibited cell invasion. Simi-
lar results were obtained in the Hs 578T breast cancer
cell line. These results suggest that CHD5 is an impor-
tant tumor suppressor gene that could modulate the
development and progression of human breast cancer.
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